Post Job Free

Resume

Sign in

Technician Medical

Location:
Columbia, MD
Salary:
80000
Posted:
March 07, 2012

Contact this candidate

Resume:

CURRICULUM VITAE

FARHAT KHAN

Citizenship: USA

Address for Correspondence: 10349 Barcan Circle, Columbia, MD 21044

Telephone No.: Work: 410-***-****, Home: 410-***-****

Email: l0w02k@r.postjobfree.com, l0w02k@r.postjobfree.com

EDUCATION

7/87-12/87 Chemical Basis/Gene Expression, University of Notre Dame, Notre Dame, IN 46556.

7/82-7/85 Doctor of Philosophy, Chemistry, Aligarh University, Aligarh, U.P., India.

5/80-6/82 Master of Philosophy, Chemistry, Aligarh University, Aligarh, U.P., India.

6/77-5/79 Master of Science, Chemistry, Aligarh University, Aligarh, U.P., India.

5/74-6/77 Bachelor of Science (Honors), Chemistry, Aligarh University, Aligarh, U.P., India.

HONORS

Siple Award at 26th Army Science Conference 2008, Orlando, Florida

Postdoctoral Trainee Fellowship, National Institute of Health, Bethesda, MD USA. 1/1994-12/1995

Research Associateship, Council of Scientific & Industrial Research, New Delhi, India, 1986.

Senior Research Fellowship, Department of Science & Technology, New Delhi, India, 1985-86.

Junior & Senior Research Fellowship Council of Scientific & Industrial Research, New Delhi, India, 1980-85

Postgraduate Merit Scholarship for Masters Degree in Chemistry, Aligarh University. 1977-79.

RESEARCH TRAINING AND EXPERIENCE

3/2007-12/2011

Principal Investigator, The Geneva Foundation/Department of Regulated Laboratories, Division of Regulated Activities, Walter Reed Army Institute of Research (WRAIR), Silver Spring, MD 20910.

1. Developed pro-2-PAM as a candidate drug to treat organophosphate toxicity.

2. Developed an HPLC assay to separate and quantify the pro-2-PAM and 2-PAM oximes.

3. Utilized spectroscopy to quantify the conversion of pro-2-PAM to 2-PAM.

4. Studied the kinetics of reactivation of diisopropyl fluorophosphate inhibited acetylcholinesterase with 2-PAM and pro-2-PAM.

5. Studied the toxicity of pro-2-PAM in cell culture model, and in mice under Good Laboratory Practices (GLP) regulation. I am experienced with FDA regulations of non-clinical health and environmental safety research

6. Cell membrane isolation for receptor binding assay.

7. Reviewed scientific data to ensure its accuracy, precision, and reliability, wrote animal protocols, and SOPs. Directed support staff, retrieved and reviewed their weekly reports.

8. Participated in writing grant proposals on neurochemical brain injury and traumatic brain injury.

9. Served as department’s Environmental Compliance Chemical Hygiene Officer (ECCHO).

10. Experienced with 96-well plate based assays using UV-Vis and Fluorescent plate reader.

9/1998-3/2007

Molecular Biologist, CRM Inc. /Division of Malaria Vaccine Development, WRAIR.

1. Constructed plasmids for expression of C3d conjugated Plasmodium berghei antigens for a new DNA vaccine, Expressed it in mammalian cells, purified, and characterized the product by Western blot assay.

2. Constructed plasmid vector for combination vaccine, this chimeric protein was expressed in E. coli and purified on Ni-NTA and GST-Sepharose affinity resin for the recombinant protein vaccine. Antibodies were raised in mice and rabbit against the fusion protein, antibody titers measured against individual components of the fusion protein. Efficacy of the antibodies was measured in a growth inhibition assay.

3. Codon harmonized Plasmodium falciparum antigens were expressed in E. coli and purified on Ni-NTA and ion-exchange chromatography for recombinant protein vaccine.

4. Constructed a plasmid vector of codon harmonized malaria antigens without His tag, and expressed in E. coli. Effect of His-tag on the proteins solubility, structure, and immune responses was studied.

5. Estimated residual endotoxins, imidazole, sarkosyl, and E. coli contaminant proteins in final recombinant vaccine product.

6. Developed ELISA and Western blot assays using conformation specific antibodies to determine native structure of recombinant vaccine product.

7. Prepared SOP’s for Batch Production Records of vaccine products. Wrote reports for the IND submission to the FDA.

1/1996-8/1998

Research Scientist, University of Maryland, Department of Animal and Avian Sciences, Bldg. 142, College Park, MD 20742.

1. Studied the developmental regulation of glucosidase I gene in mouse mammary gland. The gene was isolated and its structural organization and promoter activity was determined in primary cell culture model.

2. Supervised graduate student on the purification and characterization of glucosyltransferase from bovine mammary gland.

1/1994 -12/1995

Postdoctoral Trainee, Johns Hopkins University, Department of Psychiatry and Behavioral Sciences, Ross 618, 720 Rutland Avenue, Baltimore, MD 21205.

Studied neurodegenerative disease genes containing expanded CAG repeat, i.e. Huntington and Dentatorubral and Pallidoluysian atrophy homologs.

3/1989- 12/1993

Research Assistant, N Y U Medical Center, Department of Biochemistry, 550, First Avenue, New York, N Y 10016.

1. Cloned and Sequenced cDNA of a human hnRNP protein from Hela cells. Hela cells were grown suspension in 5 lit. stirrer flask.

2. Genetic Linkage Mapping: Refined the linkage map of mouse chromosome (Chr) 12 using hybrid cell line and established homology relationship with human chromosomes 2p and 14q3.

9/1986-2/1989

Postdoctoral Fellow, University of Notre Dame, Department of Chemistry & Biochemistry, Notre Dame, IN 46556.

Studied Regulation of glycolipid glycosyltransferases in neuroblastoma and colon carcinoma Cells.

1. Peformed in vitro biosynthesis of core lacto-series glycosphingolipids by N-acetylglucosaminyl transferases from colon carcinoma colo 205 cells.

2. Performed in vitro Biosynthesis of SA-Lex and SA-diLex using α1-3 fucosyltransferase from colon carcinoma and embryonic brain tissues.

3. Performed in vitro Biosynthesis of neolactotetrosylceramide using galactosyltransferase from mouse T-lymphoma.

4. Purified, and characterized specificity of glycosyltransferases & glycosidases.

4/1986-8/1986

Research Associate, Central Drug Research Institute, Department of Biochemistry, Lucknow, U.P. India.

Characterized amylases and amyloglucosidases.

5/1985-4/1986

Senior Research Fellow, J. N. Medical College, Department of Biochemistry, Aligarh University, Aligarh, U.P. India

1. Purified and characterized Lectins.

2. Taught Biochemistry to MS degree students.

5/1980-4/1985

Ph.D. Student, Sree Chitra Tirunal Institute for Medical Sciences & Technology, Dept. of Neurochemistry, Trivandrum, India.

Purified and characterized lysosomal enzyme α-D- mannosidase from human placental tissue (Thesis).

1. I purified Lysosomal α-D-Mannosidase from human placental tissue to homogeneity utilizing Concanvalin A (Con A)-Sepharose chromatography (affinity chromatography), heat treatment at 65ºC, ion-exchange (DEAE-Sephadex) chromatography, and size-exclusion (Sephadex G-200) chromatography. I determined the physicochemical properties, and immunological cross-reactivity of this enzyme with different organs.

2. Purification of galactose specific lectin from human placenta using lactose conjugated sepharose resin as affinity matrix, and performed physico-chemical Characterization.

TRAININGS

2010 Regulatory Overview of Drug and Biologics Development, Gaithersburg, MD.

2010 Basic Flow Cytometry Course, WRAIR, Silver Spring, MD 20910.

2009 Introduction to FDA Good Laboratory Practices, USAMRIID, Frederick, MD.

2007 Lagomorphs Handling Techniques, WRAIR, Silver Spring, MD 20910.

2007 Laboratory Animal Care Course, WRAIR, Silver Spring, MD 20910.

2007 Rodent Handling Techniques, WRAIR Silver Spring, MD 20910.

1986-2010 Radiation Safety, University of Notre Dame, IN, NYU Medical Center, NY, Johns

Hopkins University Baltimore, MD and WRAIR, Silver Spring, MD 20910

2004 Compliance with Good Manufacturing Practices (1 Semester), UMBC, MD 21244.

2004 Good Laboratory Practices (GLP) Regulation (16 h) WRAIR, Silver Spring MD 20910.

1999 Introduction to Biostatistics Course, (36 Class hours) WRAIR, Silver Spring, MD 20910.

RESEARCH TECHNICAL SKILLS

• Chromatographic techniques (Hydrophobic, Ion-exchange, affinity and size exclusion) of protein purification and biochemical Characterization, Fast Performance Liquid Chromatography (FPLC, Water’s system), High Pressure Liquid Chromatography (HPLC) Waters system and UPLC-MS/MS Waters system.

• Analyzed linkage of enzymatic products of carbohydrate molecules by smith degradation methods.

• Generated affinity matrix to purify enzymes and lectins, Performed enzyme kinetics using synthetic substrates, and inhibitors of α-D-mannosidase,

• Performed cell culture, including primary mouse mammary gland cells to study developmental regulation of glucosidase.

• Performed Iimmunological techniques: antibody production and purification, immunoprecipitation, Western transfer, and ELISA.

• Molecular experience includes plasmid transfection by chemical, electrophoretic, and lipid mediated methods in eukaryotic and prokaryotic cells; Protein expression in mammalian and bacterial cells, 10 Liter bacterial fermentation for recombinant malaria vaccine development; microfludization for bacterial cell lysis; estimation of endotoxin level in purified vaccine antigens, Southern (cDNA and genomic) and Northern transfer, cDNA and gene cloning and DNA sequencing, construction of cDNA and genomic library, high and low stringency colony hybridization, restriction fragment length polymorphism (RFLP) for genetic linkage mapping, primer extension, ribonuclease protection assay, electrophoretic mobility shift assay, PCR/real time PCR.

• Tumor production in mice with ascites fluid, handling laboratory animals including mice and rabbit.

• Plasmid construction using Vector NTI computer program.

PEER REVIEWED PUBLICATIONS

1. Histidine Affinity Tags Affect MSP1(42) Structural Stability and Immunodominance in Mice. Khan F, Legler PM, Mease RM, Duncan EH, Bergmann-Leitner ES, Angov E (2012) Biotechnol J. 7, 133-147.

2. Oxidative mechanisms for the biotransformation of 1-methyl-1,6-dihydropyridine-2-carbaldoxime to pralidoxime chloride. Khan FA, Campbell AJ, Hoyt B, Herdman C, Ku T, Thangavelu S, Gordon RK. (2011) Life Sciences. 89, 911-917.

3. Pro-2-PAM therapy for central and peripheral cholinesterases. DeMar JC, Clarkson ED, Ratcliffe RH, Campbell AJ, Thangavelu SG, Herdman CA, Leader H, Schultz SM, Marek E, Medynets MA, Ku TC, Evans SA, Khan FA, Owens RR, Nambiar MP, and Gordon RK. (2010) Chem. Biol. Interact. 187, 191-198.

4. Evaluation of immunoglobulin purification methods and their impact on quality and yield of antigen-specific antibodies. Bergmann-Leitner ES, Mease RM, Duncan EH, Khan F, Waitumbi J, and Angov E. (2008) Malaria Journal, 7: 129.

5. A critical evaluation of different methods for measuring the functional activity of antibodies against malaria blood stage. Bergmann-Leitner ES, Duncan EH, Muller GE, Burge JR, Khan F, Angov E., Lyon JA (2006) Am. J Trop. Med. Hyg. 75 (3): 437-442.

6. C3d binding to the circumsporozoite protein carboxyl-terminus deviates immunity against malaria. Bergmann-Leitner ES, Scheiblhofer S, Weiss R, Duncan EH, Leitner WW, Chen D, Angov E, Khan F, Williams JL, Winter DB, Thalhamer J, Lyon JA, Tsokos GC.(2005) Int Immunol., 17(3):245-55.

7. Removal of the circumsporozoite protein (CSP) glycosylphosphatidylinositol signal sequence from a CSP DNA vaccine enhances induction of CSP-specific TH2 type immune responses and improves protection against malaria infection. Scheiblhofer, S., Chen D., Weiss, R., Khan F., Mostbock S., Fegeding K., Leitner W. W., Thalhamer J., and Lyon J.A. (2001) Eur. J. Immunol., 31:692-698.

8. Genomic organization and promoter activity of glucosidase I gene. Khan F.A., Varma G.M and Vijay I.K (1999) Glycobiology, 8:797-806.

9. Truncated N-terminal fragments of Huntingtin with expanded glutamine repeats form nuclear and cytoplasmic aggregates in cell culture. Cooper J.K, Schilling G., Peters M.F, Herring W.J, Sharp A.H, Kaminsky Z., Masone J, Khan F. A, Delanoy M., Borchelt D.R., Dawson V.L, Dawson T.M., and Ross, C.A. (1998) Hum Mol Genet., 5:783-790.

10. Biosynthesis in vitro of neolactotetrosylceramide by a galactosyltransferase from mouse T-lymphoma: purification and kinetic studies; synthesis of neolacto and polylactosamine core. Basu M., Wang S-A, Tang H., Khan F.A., and Basu S. (1996) Glycoconjugate J, 13:423-432.

11. cDNA cloning and characterization of an atrophin -1( DRPLA disease gene) related protein. Khan F. A., Margolis R.L., Love S.L., Sharp A.H., Li S-H, and Ross, C.A. (1996) Neurobiology of Disease. 3:121-128.

12. Refinement of the DNA Marker Maps of Mouse Chromosome 12. Khan F., Clarke V., and D' Eustachio P. (1994) Genomics, 21:128-137.

13. Biosynthesis in vitro of SA-Lex and SA-diLex by α1-3 fucosyltransferase from colon carcinoma cells and embryonic brain tissues. Basu M., Hawes J.W., Li Z., Ghosh S., Khan F.A., Zhang S., and Basu, S. (1991) Glycobiology, 1:527-535.

14. Cloning and Sequence Analysis of a Human Type A/B hnRNP Protein. Khan F.A., Jaiswal A. K., and Szer, W. (1991) FEBS Lett, 290:159-161.

15. Biosynthesis in vitro of Core Lacto- Series Glycosphingolipids by N-acetylglucosaminyltransferases from Human Colon Carcinoma Colo 205. Basu M., Khan F. A., Das K.K. & Zhang, B. (1991) Carbohydrate Res, 209:261-277.

16. Solubilized Glycosyltransferases and Biosynthesis in vitro of Glycolipids. Basu, S., Shaper R.J., Das K.K., Daussin F., Banerjee P., Khan F. A., Basu M. & Suzuki, I. (1988) Biochemie, 70:1551-1563.

17. Biosynthesis in vitro of Neuronal and Non- Neuronal Gangliosides. Basu S., Daussin F., Banerjee P., Shaper R.J., Das K.K, Khan F. A., & Basu M. (1988) New Trends in Ganglioside Research: Neurochemical & Neurogenerative Aspects, Plenum Book, (Ed. Leeden, R. et.al.) Livina Press, Padova, P. 259-273.

18. Biosynthesis of Tumor Related Glycosphingolipids. Basu M., Das K.K., Zhang B., Khan F. A., and Basu S. (1988) Indian J. Biochem. Biophys., 25:112-118.

19. Characterization of Lysosomal α-D-Mannosidase from Human Placenta. Basu D., Nair J.V. and Khan, F.A. (1988) Indian J. Biochem. Biophys. 25:695-698.

20. Effect of Chemical Modification on Placental α-D-Mannosidase. Khan, F. A. & Basu D. (1984). Indian J. Biochem. Biophys, 21:203-205.

21. Isolation and Characterization of Lysosomal α-D-Mannosidase of Placental Tissue. Khan, F.A., & Basu D. (1982) J.BioSci. 4:133-138.

MENTORSHIPS

1. Therese Ku (BS): Technician, Department of Regulated Laboratories, Division of Regulated Activities, WRAIR, April 2008-Present, HPLC assay to measure stability of Pro-2-PAM.

2. Benjamin Hoyt: (undergraduate student, Connecticut State University, development of spectrophotometric assay for the conversion of Pro-2-PAM to 2-PAM in the presence of riboflavin, SEAP Program, 2009)

3. Elizabeth Marek (MS): (Technician) Department of Biochemical Pharmacology, Division of Biochemistry, WRAIR. January 2008-August 2009. Isolation of membrane fraction, and HPLC assay to measure stability of Pro-2-PAM.

4. Marie Medynets (BS): (Technician) Department of Biochemical Pharmacology, Division of Biochemistry, WRAIR. November 2007-March 2009. Kinetics of reactivation of Diisopropyl fluorophosphates inhibited Acetylcholinesterase with oximes and oxidized pro-oximes.

5. Sonia Thangavelu (BS): (Technician) Department of Biochemical Pharmacology. Division of Biochemistry, WRAIR. March 2007-December 2008. Development of in vitro assays to characterize oximes and pro-oximes.

6. Mark Ficco (BS): (Technician) Department of Biochemical Pharmacology, Division of Biochemistry, WRAIR. May 2007-December 2007. Kinetics of reactivation of Di-isopropyl fluorophosphates inhibited Acetylcholinesterase with oximes and oxidized pro-oximes.

7. Chris Burge: (Undergraduate Student at College Park) Expression, and Purification of MSP142 (FUP/CAMP) and His-tag free MSP142 (FVO) recombinant Protein. SEAP Program 2005 and 2006).

8. Govindaraj Krishnamurthy Ph.D.: (Postdoctoral Fellow USUHS) Protein expression of C3d and CSP-C3d conjugates in E. coli 2005.

9. Jessica Ackerman: (Co-operative undergraduate student from Penn State) Three Vector Systems, and Their Components, Used in Producing Plasmodium falciparum Recombinant Protein 2001.

10. Nishchhal Neelaveni: (Master’s student at University of Maryland at College Park, 1996-1997, Purification and characterization of glucosyltransferase from bovine mammary gland).

ABSTRACTS

1. Development of an in Vitro Assay for the Conversion of Pro-2-Pralidoxime to 2-Pralidoxime. Farhat A. khan, Sonia Thangavelu, Amy J. Campbell, Elizabeth Marek, Richard K. Gordon, Bioscience Review 2008 Marriot Hotel, Hunt Valley, MD.

2. Antibodies Raised Against Plasmodium falciparum MSP1-42 Expressed from a Fully Codon-Harmonized Gene Are Significantly More Growth Inhibitory Than Those Raised Against The Same Antigens Expressed From A Partially Codon-Harmonized Gene. Evelina Angov, Farhat Khan, Elke S Bergmann-Leitner, Randall Kinkaid, Donald G. Heppner, Lorraine Soisson, Joe Cohen, Carter Diggs and Jeffrey A. Lyon, 2005, ASTMH Washington DC.

3. Expression of an EBA-175(f2)/MSP142 chimeric protein in Escherichia coli for use as a two subunit malaria vaccine. Farhat A. Khan, Evelina Angov, Elke Bergmann-Leitner, Elizabeth Dunkin, Anjali Yadava, Vlad Malkov, Arnoldo Barbosa, Chris Ockenhouse, Carter Diggs and Jeffrey A. Lyon. Department of Immunology, WRAIR 503 Robert Grant Avenue, Silver Spring, MD 20910, USA. ASTMH 2002 Denver, Colorado.

REFERENCES

1. Richard K. Gordon, Ph.D.,

Pentagon, Washington DC,

Tel.: 571-***-****

cell: 240-***-****

e-mail: l0w02k@r.postjobfree.com

2. Dr. Evelina Angov, Microbiologist,

Division of Malaria Vaccine Development, Walter Reed Army Institute of Research

Silver Spring, MD 20910

Tel.: 301-***-****

3. Dr. Anjali Yadava, Micreobiologist,

Division of Malaria Vaccine Development, Walter Reed Army Institute of Research

Silver Spring, MD 20910

Tel. No. 301-***-****

4. Dr. Peter D'Eustachio, Professor

Department of Biochemistry, N Y U Medical Center, 550

First Avenue, New York, N Y 10016.

Tel: 212-***-****



Contact this candidate